HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shahrokh F Shariat Selected Research

Obesity

11/2021Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data.
1/2021Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer.
1/2021Prevalence and trends in urinary incontinence among women in the United States, 2005-2018.
1/2019Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder.
1/2017Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.
1/2016The Effect of Obesity on Perioperative Outcomes Following Percutaneous Nephrolithotomy.
2/2013Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
8/2007Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shahrokh F Shariat Research Topics

Disease

467Neoplasms (Cancer)
05/2024 - 02/2002
337Carcinoma (Carcinomatosis)
04/2024 - 12/2002
318Prostatic Neoplasms (Prostate Cancer)
04/2024 - 02/2002
306Urinary Bladder Neoplasms (Bladder Cancer)
05/2024 - 03/2002
114Renal Cell Carcinoma (Grawitz Tumor)
04/2024 - 10/2008
101Neoplasm Metastasis (Metastasis)
04/2024 - 02/2002
66Non-Muscle Invasive Bladder Neoplasms
04/2024 - 05/2010
61Lymphatic Metastasis
01/2024 - 03/2002
39Disease Progression
04/2024 - 02/2002
35Carcinoma in Situ
01/2022 - 03/2003
32Margins of Excision
11/2023 - 03/2004
28Transitional Cell Carcinoma
04/2014 - 03/2002
16Kidney Neoplasms (Kidney Cancer)
03/2024 - 09/2012
16Adenocarcinoma
06/2023 - 05/2007
15Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2023 - 03/2011
11Urologic Neoplasms (Urological Cancer)
12/2023 - 06/2013
10Intraoperative Complications
03/2024 - 04/2012
10Necrosis
11/2023 - 04/2010
10Carcinogenesis
12/2022 - 11/2007
10Inflammation (Inflammations)
06/2022 - 03/2011
9Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2023 - 01/2004
8Obesity
11/2021 - 08/2007
7COVID-19
04/2022 - 01/2020
7Extranodal Extension
03/2019 - 06/2004
6Hematuria
04/2024 - 04/2007
6Erectile Dysfunction
12/2022 - 09/2008
6Anemia
05/2021 - 02/2014
5Frailty
05/2024 - 03/2020
5Diabetes Mellitus
11/2023 - 12/2013
5Hypertension (High Blood Pressure)
11/2023 - 01/2019
5Sarcopenia
04/2023 - 01/2018
5Lower Urinary Tract Symptoms
12/2022 - 09/2008
5Residual Neoplasm
06/2022 - 08/2009
5Urinary Incontinence
01/2022 - 11/2012

Drug/Important Bio-Agent (IBA)

106Biomarkers (Surrogate Marker)IBA
11/2023 - 05/2003
57Prostate-Specific Antigen (Semenogelase)IBA
04/2024 - 10/2002
32AndrogensIBA
04/2024 - 03/2004
28Immune Checkpoint InhibitorsIBA
04/2024 - 01/2018
27Hormones (Hormone)IBA
04/2024 - 10/2002
20Cisplatin (Platino)FDA LinkGeneric
05/2024 - 06/2008
20AntigensIBA
04/2024 - 03/2008
20Docetaxel (Taxotere)FDA Link
04/2024 - 01/2018
19Proteins (Proteins, Gene)FDA Link
12/2022 - 05/2007
16nuclear matrix protein 22IBA
11/2014 - 12/2003
15Androgen Receptors (Androgen Receptor)IBA
04/2024 - 01/2008
13Indicators and Reagents (Reagents)IBA
01/2023 - 04/2010
13Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
11/2021 - 12/2002
12GemcitabineFDA Link
05/2024 - 06/2008
11pembrolizumabIBA
11/2023 - 01/2019
11AlbuminsIBA
01/2023 - 06/2014
11Interleukin-6 (Interleukin 6)IBA
01/2022 - 03/2002
11SurvivinIBA
11/2015 - 02/2004
10GlobulinsIBA
03/2022 - 01/2020
9enzalutamideIBA
12/2023 - 01/2020
9Hemoglobins (Hemoglobin)IBA
11/2023 - 02/2014
9Dihydrotachysterol (AT 10)IBA
06/2023 - 12/2009
9PlatinumIBA
02/2023 - 10/2011
9Tyrosine Kinase InhibitorsIBA
01/2022 - 09/2014
9Cadherins (E-Cadherin)IBA
08/2017 - 12/2003
8Messenger RNA (mRNA)IBA
01/2022 - 04/2003
8Urokinase Plasminogen Activator ReceptorsIBA
10/2020 - 12/2002
7NivolumabIBA
04/2024 - 01/2020
7DNA (Deoxyribonucleic Acid)IBA
03/2023 - 12/2011
7EnzymesIBA
04/2022 - 12/2002
7Plasminogen Activators (Plasminogen Activator)IBA
01/2021 - 03/2008
6LigandsIBA
08/2023 - 12/2018
6C-Reactive ProteinIBA
01/2023 - 11/2016
6Testosterone (Sustanon)FDA Link
12/2022 - 01/2008
6EndoglinIBA
01/2022 - 03/2008
6B7-H1 AntigenIBA
01/2022 - 01/2021
6CyclinsIBA
11/2016 - 12/2006
5apalutamideIBA
04/2024 - 11/2020
5darolutamideIBA
12/2023 - 11/2020
5Mitomycin (Mitomycin-C)FDA LinkGeneric
11/2023 - 05/2010
5Carboplatin (JM8)FDA LinkGeneric
05/2023 - 01/2018
5abirateroneIBA
01/2023 - 01/2020
5Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
08/2022 - 05/2004

Therapy/Procedure

280Cystectomy
03/2024 - 03/2002
257Therapeutics
05/2024 - 10/2002
191Prostatectomy (Retropubic Prostatectomy)
04/2024 - 02/2002
154Nephroureterectomy
04/2024 - 10/2008
118Lymph Node Excision (Lymph Node Dissection)
04/2024 - 03/2004
113Drug Therapy (Chemotherapy)
05/2024 - 12/2006
102Nephrectomy
03/2024 - 04/2007
86Radiotherapy
04/2024 - 04/2003
53Adjuvant Chemotherapy
12/2022 - 10/2006
49Neoadjuvant Therapy
01/2024 - 10/2006
42Castration
04/2024 - 04/2012
36Immunotherapy
04/2024 - 12/2012
25Transurethral Resection of Bladder
03/2024 - 03/2013
19Length of Stay
03/2024 - 08/2011
16Blood Transfusion (Blood Transfusions)
03/2024 - 04/2007
9Aftercare (After-Treatment)
12/2023 - 03/2004
7Precision Medicine
04/2024 - 01/2018
7Urinary Diversion (Ileal Conduit)
01/2024 - 12/2013
7Thrombectomy
06/2022 - 09/2014
6Intravesical Administration
05/2023 - 10/2013
6Brachytherapy
01/2022 - 05/2017
5Cryosurgery
01/2024 - 05/2014
5Conservative Treatment
01/2022 - 09/2008